IntelGenx Technologies Corp. (T:IGX)
Business Focus: Generic Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| Company Contact | |
| Address: | 6420 Abrams St SAINT-LAURENT QC H4S 1Y2 |
| Tel: | 1-514-3317440 |
| Website: | https://www.intelgenx.com |
| IR: | See website |
| Key People | ||
| Horst G. Zerbe Chairman of the Board | Andre Godin President, Chief Financial Officer | Dwight Gorham Chief Executive Officer |
| Tommy Kenny Vice President - Intellectual Property and Legal Affairs, General Counsel of IntelGenx Corp | David Kideckel Senior Vice President, Head of Corporate Development and Strategic Alliances of IntelGenx Corp | Nadine Paiement Vice President - Research and Development of IntelGenx Corp | Ingrid Zerbe Corporate Secretary |
| Business Overview |
| IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company's film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, IntelGenx Technologies Corp. revenues increased 9% to $1M. Net loss decreased 7% to $9.9M. Revenues reflect Sales milestone revenue segment increase from $0K to $125K, Research and development agreements segment increase of 7% to $884K, Europe segment increase of 20% to $840K, United States segment increase of 33% to $193K. Lower net loss reflects Interest income increase from $4K to $41K |
| Employees: | 48 as of Dec 31, 2019 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $59.35M as of Dec 31, 2023 |
| Annual revenue (TTM): | $1.42M as of Dec 31, 2023 |
| EBITDA (TTM): | -$11.94M as of Dec 31, 2023 |
| Net annual income (TTM): | -$13.58M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$9.18M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $17.43M as of Dec 31, 2023 |
| Shares outstanding: | 174,658,096 as of Mar 21, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.